Effect of gender, dose, and time on 3-(3,5-dichlorophenyl)-2,4- thiazolidinedione (DCPT)-induced hepatotoxicity in Fischer 344 rats

Xenobiotica

Volumn 38, Issue 4, 2008, Pages 435-449

  Patel, N N ^a   Crincoli, C M ^a   Kennedy, E L ^a   Frederick, D M ^a   Tchao, R ^a   Harvison, P J ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

3 (3,5 dichlorophenyl) 2,4 thiazolidinedione (DCPT); Hepatotoxicity; Rats; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 (3,5 DICHLOROPHENYL) 2,4 THIAZOLIDINEDIONE; ALANINE AMINOTRANSFERASE; CORN OIL; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BIOTRANSFORMATION; DOSE RESPONSE; FEMALE; FISCHER 344 RAT; LIVER INJURY; LIVER TOXICITY; MALE; NONHUMAN; RAT; SEX DIFFERENCE;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HYPOGLYCEMIC AGENTS; LIVER; MALE; RATS; RATS, INBRED F344; SEX CHARACTERISTICS; THIAZOLIDINEDIONES; TIME FACTORS;

RATTUS;

EID: 40749102193     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250701830267     Document Type: Article

References (44)

1. Alvárez-Sanchez R, Montavon F, Hartung T, Pähler A. 2006. Thiazolidinedione bioactivation: A comparison of the bioactivation potentials of troglitazone, rosiglitazone and pioglitazone using stable isotope-labeled analogues and liquid chromatography tandem mass spectrometry. Chemical Research in Toxicology 19:1106-1116.
2. Baughman TM, Graham RA, Wells-Knecht K, Silver IS, Tyler LO, Wells-Knecht M, Zhao K. 2005. Metabolic activation of pioglitazone identified from rat and human liver microsomes and freshly isolated hepatocytes. Drug Metabolism and Disposition 33:733-738.
3. Bonkovsky HL, Azar R, Bird S, Szabo G, Banner B. 2002. Severe cholestatic hepatitis caused by thiazolidinediones: Risks associated with substituting rosiglitazone for troglitazone. Digestive Diseases and Sciences 47:1632-1637.
4. Bruno G, Costantino L, Curinga C, Maccari R, Monforte F, Nicolò F, Ottanà R, Vigorita MG. 2002. Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones. Bioorganic and Medicinal Chemistry 10:1077-1084.
5. Chojkier M. 2005. Troglitazone and liver injury: In search of answers. Hepatology 41:237-246.
6. Cullen JM. 2005. Mechanistic classification of liver injury. Toxicologic Pathology 33:6-8.
7. Czerniak R. 2001. Gender-based differences in pharmacokinetics in laboratory animal models. International Journal of Toxicology 20:161-163.
8. Forman LM, Simmons DA, Diamond RH. 2000. Hepatic failure in a patient taking rosiglitazone. Annals of Internal Medicine 132:118-121.
9. Fujinami A, Ozaki T, Yamamoto T. 1971. Antimicrobial activity of 3-phenyloxazolidine-2,4-diones and related compounds. Agricultural and Biological Chemistry 35:1707-1719.
10. Gitlin N, Julie NL, Spurr CL, Lim KN, Juarbe HM. 1998. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Annals of Internal Medicine 129:36-38.
11. Gouda HE, Khan A, Schwartz J, Cohen RI. 2001. Liver failure in a patient treated with long-term rosiglitazone therapy. American Journal of Medicine 111:584-585.
12. Graham DJ, Green L, Senior JR, Nourjah P. 2003. Troglitazone-induced liver failure: A case study. American Journal of Medicine 114:299-306.
13. Hauner H. 2002. The mode of action of thiazolidinediones. Diabetes/Metabolism Research and Reviews 18:S10-S15.
14. He K, Talaat RE, Pool WF, Reily MD, Reed JE, Bridges AJ, Woolf TF. 2004. Metabolic activation of troglitazone: Identification of a reactive metabolite and mechanisms involved. Drug Metabolism and Disposition 32:639-646.
15. Hong SK, Anestis DK, Valentovic MA, Ball JG, Brown PI, Rankin GO. 2001. Gender differences in the potentiation of N-(3,5-dichlorophenyl)succinimide metabolite nephrotoxicity by phenobarbital. Journal of Toxicology and Environmental Health, Part A 64:241-256.
16. Hong SK, Anestis DK, Valentovic MA, Ball JG, Brown PI, Wang R-T, Rankin GO. 1998. Gender differences in acute N-(3,5-dichlorophenyl)-2- hydroxysuccinimide (NDHS) and N-(3,5-dichlorophenyl)-2-hydroxysuccinamic acid (2-NDHSA) nephrotoxicity in Fischer 344 rats. Journal of Toxicology and Environmental Health, Part A 54:613-632.
17. Janakat S, AL-merie H. 2002. Optimization of the dose and route of injection, and charaterisation of the time course of carbon tetrachloride- induced hepatotoxicity in the rat. Journal of Pharmacological and Toxicological Methods 48:41-44.
18. Kassahun K, Pearson PG, Tang W, McIntosh I, Leung K, Elmore C, Dean D, Wang R, Doss G, Baillie TA. 2001. Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chemical Research in Toxicology 14:62-70.
19. Kennedy EL, Tchao R, Harvison PJ. 2003. Nephrotoxic and hepatotoxic potential of imidazolidinedione-, oxazolidinedione-, and thiazolidinedione- containing analogues of N-(3,5-dichlorophenyl)succinimide (NDPS) in Fischer 344 rats. Toxicology 186:79-91.
20. Kohlroser J, Mathai J, Reichheld J, Banner BF, Bonkovsky HL. 2000. Hepatotoxicity due to troglitazone: Report of two cases and review of adverse events reported to the United States Food and Drug Administration. American Journal of Gasteroenterology 95:272-276.
21. Limaye PB, Apte UM, Shankar K, Bucci TJ, Warbritton A, Mehendale HM. 2003. Calpain released from dying hepatocytes mediates progression of acute liver injury induced by model hepatotoxicants. Toxicology and Applied Pharmacology 191:211-226.
22. Lin G, Cui Y-Y, Liu X-Q. 2003. Gender differences in microsomal metabolic activation of hepatotoxic clivorine in rat. Chemical Research in Toxicology 16:768-774.
23. Lindros KO. 1997. Zonation of cytochrome P450 expression, drug metabolism and toxicity in liver. General Pharmacology 28:191-196.
24. Maeda K. 2001. Hepatocellular injury in a patient receiving pioglitazone. Annals of Internal Medicine 135:306.
25. Marcy TR, Britton ML, Blevins SM. 2004. Second-generation thiazolidinediones and hepatotoxicity. Annals of Pharmacotherapy 38:1419-1423.
26. Masubuchi Y. 2006. Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: A review. Drug Metabolism and Pharmacokinetics 21:347-356.
27. May LD, Lefkowitch JH, Kram MT, Rubin DE. 2002. Mixed hepatocellular-cholestatic injury after pioglitazone therapy. Annals of Internal Medicine 136:449-452.
28. Mugford CA, Kedderis GL. 1998. Sex-dependent metabolism of xenobiotics. Drug Metabolism Reviews 30:441-498.
29. Mulder G. 1986. Sex differences in drug conjugation and their consequences for drug toxicity. Sulfation, glucuronidation and glutathione conjugation. Chemico-Biological Interactions 57:1-15.
30. Nelson SD. 1995. Mechanisms of the formation and disposition of reactive metabolites that can cause acute liver injury. Drug Metabolism Reviews 27:147-177.
31. Ohbayashi H, Sasaki T, Matsumoto M, Noguchi T, Yamazaki K, Aiso S, Nagano K, Arito H, Yamamoto S. 2007. Dose- and time-dependent effects of 2,3,7,8-tetrabromodibenzo-p-dioxin on rat liver. Journal of Toxicological Sciences 32:47-56.
32. Ong MMK, Latchoumycandane C, Boelsterli UA. 2007. Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities. Toxicological Sciences 97:205-213.
33. Raheja KL, Linscheer WG, Cho C. 1983. Hepatotoxicity and metabolism of acetaminophen in male and female rats. Journal of Toxicology and Environmental Health 12:143-158.
34. Rakowitz D, Maccari R, Ottanà R, Vigorita MG. 2006. In vitro aldose reductase inhibitory activity of 5-benzyl-2,4-thiazolidinediones. Bioorganic and Medicinal Chemistry 14:567-574.
35. Rankin GO. 1982. Nephrotoxicity following acute administration of N-(3,5-dichlorophenyl)succinimide in rats. Toxicology 23:21-31.
36. Rankin GO. 2004. Nephrotoxicity induced by C- and N-arylsuccinimides. Journal of Toxicology and Environmental Health, Part B 7:399-416.
37. Rankin GO, Cressey-Veneziano K, Brown PI. 1984. Onset of and recovery from acute N-(3,5-dichlorophenyl)-succinimide-induced nephrotoxicity in Sprague-Dawley rats. Toxicology 30:205-216.
38. Sahi J, Black CB, Hamilton GA, Zheng X, Jolley S, Rose KA, Gilbert D, LeCluyse EL, Sinz MW. 2003. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metabolism and Disposition 31:439-446.
39. Scheen AJ. 2001. Hepatotoxicity with thiazolidinediones: Is it a class effect? Drug Safety 24:873-888.
40. Schwartz S, Raskin P, Fonseca V, Graveline JF. 1998. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. New England Journal of Medicine 338:861-866.
41. Sharyo S, Sagisaka H, Tanak K, Ogata S, Furukawa T, Takaoka M, Manabe S. 2001. Troglitazone, pioglitazone and rosiglitazone induce fatty changes in the liver of db/db mice. Toxicologist 60, 349 (abstract no. 1660).
42. Stine ER, Gunawardhana L, Sipes IG. 1991. The acute hepatotoxicity of the isomers of dichlorobenzene in Fischer-344 and Sprague-Dawley rats: Isomer-specific and strain-specific differential toxicity. Toxicology and Applied Pharmacology 109:472-481.
43. Tettey JN, Maggs JL, Rapeport WG, Primohamed M, Park BK. 2001. Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo. Chemical Research in Toxicology 14:965-974.
44. Willson TM, Brown PJ, Sternbach DD, Henke BR. 2000. The PPARs: From orphan receptors to drug discovery. Journal of Medicinal Chemistry 43:527-550.